UK
Scotland approves targetted combination therapy for advanced melanoma
February 11, 2020Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma
The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …
Funding cuts and government inaction has led to soaring STI rates in Britain, new study finds
February 5, 2020Research and Development AIDS, HIV, STDs, STIs, UK, sexual health
The UK faces a new Sexually Transmitted Infection (STI) diagnoses every 70 seconds, according to a new report that outlines …
Read the January/February 2020 edition of Pharmafocus online now!
January 30, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, UK, US, brexit, coronavirus, opioid crisis, pharma
Pharmafocus returns for the New Year with its January/February issue, and things have certainly changed since we left. Brexit got …
NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use
January 27, 2020Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda
NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …
NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia
January 23, 2020Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia
The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …
Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer
January 16, 2020Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza
It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …
NICE shoots down Keytruda in head and neck cancer over data concerns
January 16, 2020Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma
It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …
Scotland leading the UK in life science start-up growth, report reveals
November 20, 2019Research and Development, Sales and Marketing BioCity, UK, biotech, pharma
A new report published by the life science incubator and business collective BioCity has painted a promising picture of UK …
UKRI and BBSRC award £170m to 3 UK universities for biotech and biology PhD studentships
October 28, 2019Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, pharma, research
The Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) have awarded a funding injection of …
“No deal” Brexit and life sciences: What happens?
October 21, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Europe, UK, brexit, no deal, no-deal, pharma
Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …
Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer
October 7, 2019Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma
The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …
NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland
September 26, 2019Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma
NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …
Ireland will not suffer immediate medicine shortages in event of no-deal Brexit, says health authority
September 5, 2019Medical Communications, Sales and Marketing England, Ireland, UK, brexit, pharma
Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the …
NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy
September 4, 2019Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma
NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
University of Limerick’s Pharmaceutical Manufacturing Technology Centre to expand operations with €5m funding injection
September 3, 2019Manufacturing and Production Ireland, UK, pharma
The Pharmaceutical Manufacturing Technology Centre (PMTC) at the University of Limerick’s Bernal Institute in Ireland has secured €5 million ($5.5 …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
